Yang, Shi-jun, He, Gui-nv, Han, Xiong, Wang, Na, Chen, Yi, Zhu, Xue-rui, Ma, Bing-qian, Li, Ming-min, Zhao, Pan, Chen, Ya-nan, Zhao, Ting, and Ma, Huan
Antiepileptic drugs (AEDs) are the first choice in magnetic resonance imaging (MRI)-negative patients with epilepsy, although the responses to AEDs are diverse. Preoperative evaluation and postoperative prognosis in MRI-negative epilepsy have been reported. However, there are few tools for predicting the response to AEDs. Herein, we developed an AED response scale based on clinical factors and video-electroencephalography (VEEG) in MRI-negative patients with epilepsy. A total of 132 consecutive patients with MRI-negative epilepsy at the Epilepsy Center of Henan Provincial People's Hospital between August 2016 and August 2018 were included. Patients were further divided into drug-responsive epilepsy ([DSE-MRI (−)]; n = 101) and drug-resistant epilepsy ([DRE-MRI (−)]; n = 31) groups. The clinical and VEEG factors were evaluated in univariate analyses and multivariate logistic regression analyses. A scale was derived and the scores categorized into 3 risk levels of DRE-MRI (−). A scale was established based on 4 independent risk factors for DRE-MRI (−). The scale had a sensitivity of 83.87%, specificity of 80.20%, positive likelihood ratio of 4.24, negative likelihood ratio of 0.20, and showed good discrimination with the area under the curve (AUC) of 0.886 (0.826–0.946). The categorization of the risk score based on this scale was: low risk (0–3 points), medium risk (3–5 points), and high risk (> 5 points). We established a DRE-MRI (−) scale with a good sensitivity and specificity, which may be useful for clinicians when making medical decisions in patients with MRI-negative epilepsy. • AEDs are the first choice in MRI-negative epilepsy patients. • A scale was established based on clinical factors and VEEG, which showed a good discrimination and may be useful for making medical decisions in patients with MRI-negative epilepsy. • The risk lever was categorized as low risk (0–3 points), medium risk (3–5 points), and high risk (> 5 points) [ABSTRACT FROM AUTHOR]